Overall verdict
Neutral
5.3/10
1-year performance
+152.02%
Score breakdown
Up 152.0% over 1 year, 99% of the 52-week range.
Strongest: Profitability 9.6/10. Weakest: Growth 0.8/10.
21 analysts, target -0.3% vs the price.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation ; whole-genome sequencing kits, which sequence entire genomes of various size and complexity ;
and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.
The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem ; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research.
It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Sector
Health Care
Industry
Life Sciences Tools and Services
Primary listing
Nasdaq
United States
CEO
Jacob Thaysen
Founded
1998
Employees
8 600
Revenue / employee
504 419 USD
Next earnings
October 30, 2026 (estimated)
Institutional holders
- BlackRock, Inc.13.74%
- Capital World Investors11.04%
- VANGUARD PORTFOLIO MANAGEMENT LLC4.74%
- VANGUARD CAPITAL MANAGEMENT LLC4.71%
- STATE STREET CORP4.66%
- WCM INVESTMENT MANAGEMENT, LLC4.44%
- FMR LLC3.24%
- AQR CAPITAL MANAGEMENT LLC2.54%
- PRIMECAP MANAGEMENT CO/CA/2.52%
- Other institutions59.98%
931 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
277.95 USD
52-week low
88.00 USD
1-year performance
152.02%
Rising
Year-to-date performance
94.46%
Rising
Drawdown
-0.70%
Near its high
Position in the 52-week range
99% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned less, while shaking 3.6 times harder.
10,000 € placed at the end of September 2009 are worth today
| Illumina | 64 959 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 3.6 times as much as the world ETF.
- Worst fall:-86 % between August 2021 and April 2025. 10,000 € placed at the top fell to 1 441 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
Illumina earned less than the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Illumina: 64 959 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 123.65 USD - 141.67 USD (3 methods agree)
The price implies growth of 14.53% per year; the company grows at 4.22%.
Gross margin 66.8%, net margin 18.4%, ROIC 18.2%, ROE 32.4%.
Net margin
18.35%
Exceptional
Sector 5.47%|S&P 12.97%
Gross margin
66.81%
Exceptional
Return on equity (ROE)
32.38%
Exceptional
Sector 3.01%|S&P 16.52%
Return on invested capital (ROIC)
18.21%
Exceptional
Free cash flow margin (FCF)
20.71%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.13x
High
Margin stability
37.7 pts
Very uneven
Revenue to net income
Growth
0.8/10Revenue up 9.8% over 1 year, 6.0% a year over 5, EPS 4.2% a year over 5.
Revenue (trailing 12 months)
4.5Md USD
Revenue growth (1y)
9.84%
Solid
Revenue growth (3y)
-5.37%
Declining
EPS growth (1y)
-9.61%
Declining
EPS CAGR (5y)
4.22%
Low
EPS revisions (3 months)
2.40%
Revised up
Valuation
2.8/10P/E 51.4x, forward P/E 55.8x, EV/EBITDA 32.8x, PEG 12.20. The multiple sits in the 69th percentile of its own 5-year history.
P/E (TTM)
51.4x
Fair
Sector 50.2x|S&P 23.0x
Forward P/E
55.8x
Expensive
EV / EBITDA
32.8x
Fair
Sector 28.3x|S&P 14.5x
PEG
12.20
Very expensive
Sector 1.76|S&P 0.86
Fair value (reverse DCF)
132.66 USD
Deeply overvalued
P/E vs its own 5-year history
among the 31% highest valuations
Pricier than usual
Market cap
38.6Md USD
Financial strength
8.1/10Cash covers 46.2% of the debt, net debt/EBITDA 0.8x.
Net debt / EBITDA
0.8x
Solid
Gearing (net debt / equity)
47.89%
Solid
Cash
1.2Md USD
Cash / market cap
3.03%
Tight
Cash / total debt
46.22%
Solid
Interest coverage
8.9x
Solid
Net debt
1.4Md USD
Equity
2.8Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 273.87 USD
- MM20225.04
- MM50209.20
- MM200158.57
- RSI 1476.8
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+7.14%
200-day average slope, 3 months
+23.74%
50-day average slope, 1 month
+10.13%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
3.61 % per day
Volatility change
+37.18%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 4.95 (8) | 5.36 (21) | 4 624 (19) | 1 310 (7) | 772 (7) |
| 2027 | 5.92 (8) | 6.10 (21) | 4 919 (19) | 1 470 (7) | 912 (7) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 24, 2026.
Same sub-industry: 103 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 603259 | 8.0 | 8.0 | 75.1Md USD | 22.2x | 40.2 % | 47.7 % | 29.5 % | -1.7x | 2.6 % | 56.1 % | ||
| 2 | A207940 | 7.5 | 7.9 | 46.0Md USD | 31.8x | 39.9 % | 30.2 % | 16.6 % | -0.2x | 2.3 % | -13.0 % | ||
| 3 | IQV | 6.8 | 7.0 | 44.1Md USD | 33.2x | 8.1 % | 8.8 % | 6.8 % | 4.1x | 5.0 % | 47.6 % | ||
| 4 | A | 6.7 | 7.2 | 46.6Md USD | 32.5x | 19.5 % | 8.1 % | 13.9 % | 0.9x | 2.7 % | 38.1 % | ||
| 5 | DHR | 6.4 | 6.5 | 156Md USD | 39.3x | 15.9 % | 5.5 % | 5.4 % | 2.0x | 3.5 % | 18.6 % | ||
| 6 | LONN | 6.3 | 6.1 | 46.4Md USD | Not meaningful (loss) | 16.7 % | 19.2 % | 8.7 % | 1.9x | 0.6 % | 6.1 % | ||
| 7 | TMO | 6.0 | 5.9 | 246Md USD | 35.8x | 15.0 % | 10.5 % | 7.9 % | 2.8x | 3.0 % | 45.0 % | ||
| 8 | ILMN | 5.3 | 5.0 | 38.6Md USD | 51.4x | 18.4 % | 9.8 % | 18.2 % | 0.8x | 2.4 % | 152.0 % | ||
| 9 | WAT | 4.8 | 3.8 | 41.3Md USD | 105.0x | 3.6 % | 113.3 % | 1.4 % | 0.8x | 0.9 % | 44.7 % |
